Literature DB >> 9126268

Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations.

P Gluschankof1, I Mondor, H R Gelderblom, Q J Sattentau.   

Abstract

During preliminary experiments to establish the proportion of virus-coded p24 protein to virus membrane-associated HLA-DR in gradient-enriched HIV-1 preparations, we became aware of a large variability between experiments. In order to determine whether HLA-DR-containing cellular material was contaminating the virus preparations, we carried out enrichment by gradient centrifugation of clarified supernatants from noninfected cells and tested this material for HLA-DR content. We found that, independently of the cell type used, gradient enrichment resulted in the isolation of large quantities of HLA-DR-containing material which banded at a density overlapping that of infectious HIV. Electron microscopy of gradient-enriched preparations from supernatants of virus-infected cells revealed an excess of vesicles with a size range of about 50-500 nm, as opposed to a minor population of virus particles of about 100 nm. Electron micrographs of infected cells showed polarized vesiculation of the cell membrane, and virus budding was frequently colocalized with nonviral membrane vesiculation. Analysis of the cellular molecules present in the fractions containing virus or exclusively cellular material demonstrated that virus and cellular vesicles share several cellular antigens, with the exception of CD43 and CD63, found mainly at the virus surface, and HLA-DQ, which was found only in the cellular vesicles.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126268     DOI: 10.1006/viro.1997.8453

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  84 in total

Review 1.  CD43, a molecule with multiple functions.

Authors:  Y Rosenstein; A Santana; G Pedraza-Alva
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Minimal exclusion of plasma membrane proteins during retroviral envelope formation.

Authors:  M Hammarstedt; K Wallengren; K W Pedersen; N Roos; H Garoff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

3.  N-terminal cleavage fragment of glycosylated Gag is incorporated into murine oncornavirus particles.

Authors:  R Fujisawa; F J McAtee; C Favara; S F Hayes; J L Portis
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Lipid rafts and pseudotyping.

Authors:  W F Pickl; F X Pimentel-Muiños; B Seed
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Functional surfaces of the human immunodeficiency virus type 1 capsid protein.

Authors:  Uta K von Schwedler; Kirsten M Stray; Jennifer E Garrus; Wesley I Sundquist
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

Review 6.  Microvesicles and viral infection.

Authors:  David G Meckes; Nancy Raab-Traub
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

7.  Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages.

Authors:  Elena Chertova; Oleg Chertov; Lori V Coren; James D Roser; Charles M Trubey; Julian W Bess; Raymond C Sowder; Eugene Barsov; Brian L Hood; Robert J Fisher; Kunio Nagashima; Thomas P Conrads; Timothy D Veenstra; Jeffrey D Lifson; David E Ott
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

8.  Lipid biosensor interactions with wild type and matrix deletion HIV-1 Gag proteins.

Authors:  Eric Barklis; August O Staubus; Andrew Mack; Logan Harper; Robin Lid Barklis; Ayna Alfadhli
Journal:  Virology       Date:  2018-03-15       Impact factor: 3.616

Review 9.  The roles of tetraspanins in HIV-1 replication.

Authors:  Markus Thali
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

10.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.